

# The Canadian Journal of Neurological Sciences

# Le Journal Canadien des Sciences Neurologiques

John L. Silversides — In Memoriam ..... 217  
 Morrison H. Finlayson — In Memoriam ..... 219

## SPECIAL FEATURES

**THE 1982 SILVERSIDES LECTURE — Problems in the Diagnosis and Treatment of Pseudotumour Cerebri** ..... James J. Corbett 221  
**PRESIDENTIAL ADDRESS: XVIII CANADIAN CONGRESS OF NEUROLOGICAL SCIENCES — The Neurologist as Educator** ..... T.J. Murray 230

## ORIGINAL ARTICLES

**CSF Myelin Basic Protein Levels in Acute Optic Neuritis and Multiple Sclerosis** ..... K.G. Warren, Ingrid Catz, and T.A. McPherson 235  
**Myelin Basic Protein: A Component of Circulating Immune Complexes in Multiple Sclerosis** ..... Mrinal K. Dasgupta, Ingrid Catz, Kenneth G. Warren, Thomas A. McPherson, John B. Dosseter and Patrick R. Carnegie 239

**Computed Tomography in the Evaluation of Plexopathies and Proximal Neuropathies** ..... John D. Stewart, Brian Schmidt and Roberto Wee 244

**Correlation of Computed Tomography with Surgical Diagnosis in Lumbar Disc Disease** ..... Robert Griebel, Stanley Tchang, Moe Khan and George Varughese 248

**Digital Nerve Sensory Potentials in Lesions of Cervical Roots and Brachial Plexus** ..... Michael Newman and Norma Nelson 252

**The Pattern Electroretinogram in Optic Nerve Demyelination** ..... Trevor H. Kirkham and Stuart G. Coupland 256

**Multimodal Electrophysiological Assessment of Ataxia** ..... Margot J. Taylor and William J. Logan 261

**Cauda Equina Paraganglioma** ..... Ming-Sound Tsao, Juan Bilbao, Peter Richardson and Morrison Finlayson 266

**Background Vascular Headache: Relief with Indomethacin** ..... Dan Boghen and Nicole Desaulniers 270

BOOK REVIEWS ..... 272

NOTES AND ANNOUNCEMENTS ..... 274

INDEX TO VOLUME 10 — 1983 ..... 276



XIX Canadian Congress of  
 Neurological Sciences  
 Edmonton, Alberta


June 26 - 30, 1984

Call for Abstracts page 279

## The Official Journal of

The Canadian Neurological Society  
 The Canadian Neurosurgical Society  
 The Canadian Society of Clinical Neurophysiologists  
 The Canadian Association for Child Neurology

# you wouldn't guess Jane's an epileptic



**Epileptic therapy doesn't have to interfere with her life. Depakene can effectively control seizures, with little risk of disturbed behaviour or poor performance.**

**Depakene provides broad-spectrum seizure control** Depakene is considered a drug of first choice for simple and complex absence seizures<sup>1,2</sup> and has been successfully used in tonic-clonic or myoclonic seizures with absence components.<sup>3,4</sup>

**No impairment of learning** Depakene has made patients more alert, more lively and better able to perform daily tasks.<sup>5</sup>

**Positive effect on behaviour** Depakene, unlike phenobarbital, rarely affects behaviour, and may actually improve it.<sup>5</sup>

**Low incidence of disturbing side effects** Depakene does not cause hirsutism, gum hyperplasia or acne, nor has it been associated with aplastic anemia or agranulocytopenia.

**Minimizes problems of polypharmacy** Depakene is often effective as single therapy. When other anticonvulsants are necessary, their dosage may be reduced.

**New dosage convenience** A 500-mg enteric-coated capsule is now available.

valproic acid  
**Depakene**<sup>\*</sup>  
brings many epileptic patients closer to normal

 PHARMACEUTICAL PRODUCTS DIVISION  
ABBOTT LABORATORIES, LIMITED  
MONTREAL, CANADA H4P 1A5

See page x

\*TM  

# THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES

## Editor

Robert G. Lee  
Calgary

## Associate Editor

André Barbeau  
Montreal

## Founding Editor

Robert T. Ross  
Winnipeg

## Editorial Board

Albert J. Aguayo  
Montreal

Henry J.M. Barnett  
London

Paul Bédard  
Quebec

Henry B. Dinsdale  
Kingston

Guy Geoffroy  
Montreal

Alan Hudson  
Toronto

Yves Lamarre  
Montreal

Bernard Lemieux  
Sherbrooke

William J. Logan  
Toronto

Morton Low  
Vancouver

Thomas P. Morley  
Toronto

Thomas J. Murray  
Halifax

Donald Paty  
Vancouver

Sidney J. Peerless  
London

Terry Picton  
Ottawa

Jean Reiher  
Sherbrooke

Leo P. Renaud  
Montreal

Barry Rewcastle  
Calgary

Matthew W. Spence  
Halifax

William G. Tatton  
Toronto

Bryce Weir  
Edmonton

## Book Review Editor

T. Peter Seland  
Calgary

## Editorial Assistant

Sally Gregg  
Calgary

THE EDITORIAL BOARD wishes to publish original work in the basic and clinical neurosciences on the understanding that it has not been and will not be published elsewhere. Review articles on timely subjects will be accepted. Manuscripts must be in triplicate including illustrations. One of the copies must be the original, ribbon copy. Manuscripts should be typed double spaced, on white paper.

Papers will be accepted in French or English. All papers should be accompanied by a short résumé in both languages. The résumé translation will be done by the editorial board if requested.

Papers should be identified only by the full name of the author, or authors, and the name of the place in which the work was done.

**ILLUSTRATIONS:** Photographs should be unmounted on glossy paper and show magnification scale. They should be marked on the back with figure number, title of paper and name of author.

Diagrams should be in India ink and large enough to be informative after reduction.

All illustrations should be referred to as figures, numbered consecutively, not included in the body of the text and all captions

should be typed on a separate piece of paper.

Colored illustrations cannot usually be accepted unless the author is prepared to assist with the cost of reproduction.

**REFERENCES** to authors outside the context of the sentence should read (Name, Year). i.e. "However, a recent study (Bird and Iverson, 1975) showed a decreased, etc." Authors mentioned within the context of the sentence should read Name (Year), "i.e. . . . twenty years since Ecker and Reimenshender (1951) demonstrated, etc." References should be typed in alphabetical order on a separate sheet and include author's name, initials, year, title, publication, volume first and last page, i.e. Isacson, P. (1967). Myx-oviruses and autoimmunity. *Progress in Allergy*, 10, 256-292. Abbreviations should be the same as those used in *Cumulated Index Medicus*.

Textbook references should include name of text, author's name, page number, publisher and city.

**REPRINTS:** Fifty reprints will be supplied free if ordered when the galley proofs are returned. More may be ordered at a nominal charge. Corrections and changes in the galley proofs, apart from printer's errors may be charged to the author.

This journal is indexed by **Index Medicus**, **Excerpta Medica** and **Current Contents — Clinical Practice and Life Science**.

**SUBSCRIPTIONS:** This journal is issued four times a year. The annual rate is \$40.00 for Canada and the U.S.A. \$44.00 elsewhere. Internes, Residents, Pre- and Post-Doctoral Students, \$20.00 per annum. Single copies \$12.00 each.

**ADVERTISING:** Enquiries regarding advertising space and rates should be directed to LEX LTD. VANCO PUBLICATIONS, 431 Alden Road, Markham, Ontario L3R 3L4. Telephone — (416) 477-2030.

All communications, manuscripts, subscriptions, etc., should be sent to the Editor, Canadian Journal of Neurological Sciences, Faculty of Medicine, 2500 University Drive, Calgary, Alberta, Canada T2N 1N4.

**COPYRIGHT** © 1983 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. ISSN 0317-1671.

Published in conjunction with the University of Calgary Press.

Printed by McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5  
Mailed under second class registration number 3307. Postage paid at Calgary, Alberta.

## **PUBLICATIONS COMMITTEE**

Donald Baxter  
Montreal

Andrew Eisen  
Vancouver

Terry Myles  
Calgary

## **CANADIAN NEUROLOGICAL SOCIETY**

President  
Past-President  
Vice-President  
Secretary-Treasurer

Thomas J. Murray  
Henry B. Dinsdale  
Robert F. Nelson  
Garth M. Bray  
1650 Cedar Avenue  
Montreal, P.Q.  
H3G 1A4

Council:  
Monique Lefebvre-d'Amour  
Jean Pierre Bouchard  
William McCormick  
Donald Calne  
Ali Rajput  
Peter Seland

## **CANADIAN NEUROSURGICAL SOCIETY**

President  
Past-President  
President-Elect  
Secretary-Treasurer

Stuart Huestis  
Leslie Ivan  
Stanley Schatz  
Gary Ferguson  
University Hospital  
London, Ontario  
N6A 5A5

Council:  
Jacques Boucher  
Derek Fewer  
Mohamed Khan  
Hart Schutz  
Andre Olivier  
Barry Purves

## **CANADIAN SOCIETY OF CLINICAL NEUROPHYSIOLOGISTS**

President  
Past-President  
Secretary-Treasurer

Warren Blume  
Andrew Eisen  
Terry Picton  
Ottawa General Hospital  
501 Chemin Smythe Road  
Ottawa K1H 8L6

Council:  
Roger Broughton  
Reda El-Sawy  
Normand Giard  
Leroy Heffernan  
Sherrill Purves

## **CANADIAN ASSOCIATION FOR CHILD NEUROLOGY**

President  
Past-President  
Vice-President  
Secretary-Treasurer

Frederick Andermann  
Rosalind Curtis  
R. Haslam  
Daune L. McGregor  
Hospital for Sick Children  
555 University Ave.  
Toronto M5G 1X8

Council:  
Peter Humphreys  
J.U. Crichton  
A. Larbrisseau



**Lioresal**<sup>®</sup>  
baclofen



**Treating spasticity  
right at the start**

**gives him a  
better start on the  
tough road back.**

Early intervention with Lioresal can significantly enhance successful rehabilitation, especially before major disabilities become permanent!<sup>1</sup>

- Lioresal helps relieve spasticity resulting from spinal cord injury, multiple sclerosis or other spinal cord disorders.
- Lioresal acts primarily at the spinal level eliminating the problem of troublesome over sedation?
- Lioresal improves overall outlook for long term management!<sup>1</sup>

**Lioresal**<sup>®</sup>

**sooner...  
means a  
fuller life later.**

PAAB  
CCPP  
G-3017

See page xiv

**Geigy**  
Mississauga, Ontario  
L5N 2W5

## Brief Prescribing Information

# Tegretol® No substitution.

### 200 mg carbamazepine

#### Indications and clinical use

##### a) *Trigeminal Neuralgia:*

Tegretol is indicated for the symptomatic relief of pain of trigeminal neuralgia only during periods of exacerbation of true or primary trigeminal neuralgia (tic douloureux). It should not be used preventively during periods of remission. In some patients, Tegretol has relieved glossopharyngeal neuralgia. For patients who fail to respond to Tegretol, or who are sensitive to the drug, recourse to other accepted measures must be considered. Tegretol is not a simple analgesic and should not be used to relieve trivial facial pains or headaches.

##### b) *Tegretol has been found useful:*

1. in the management of psychomotor (temporal lobe) epilepsy and,
2. as an adjunct, in some patients with secondary or partial epilepsy with complex symptomatology or secondarily generalized seizures, when administered in combination with other antiepileptic medication.
3. as an alternative medication in patients with generalized tonic-clonic seizures who are experiencing marked side effects or fail to respond to other anticonvulsant drugs.

Tegretol is essentially ineffective in controlling petit mal, minor motor, myoclonic and predominantly unilateral seizures, and does not prevent the generalization of epileptic discharge.

#### Contraindications

Tegretol should not be administered to patients with a history of hepatic disease or serious blood disorder.

Tegretol should not be administered immediately before, in conjunction with, or immediately after a monoamine oxidase inhibitor. When it seems desirable to administer Tegretol to a patient who has been receiving an MAO inhibitor, there should be as long a drug-free interval as the clinical condition allows, but in no case should this be less than 14 days. Then the dosage of Tegretol should be low initially, and increased very gradually.

Tegretol should not be administered to patients presenting atrioventricular heart block.

Safe use in pregnancy has not been established. Therefore, Tegretol should not be administered during the first three months of pregnancy.

Tegretol should not be given to women of child-bearing potential unless, in the opinion of the physician, the expected benefits to the patient outweigh the possible risk to the foetus (See Reproductive Studies). Because of demonstrated toxicity in nursing animals, Tegretol should not be administered to nursing mothers.

Because of the similarity of chemical structure, Tegretol should not be administered to patients with known hypersensitivity to any of the tricyclic compounds, such as amitriptyline, trimipramine, imipramine, or their analogues or metabolites.

#### Warnings

Although reported infrequently, serious adverse effects have been observed during the use of Tegretol. Agranulocytosis and aplastic anemia have occurred in a few instances with a fatal outcome. Leucopenia, thrombocytopenia and hepatocellular and cholestatic jaundice have also been reported. It is, therefore, important that Tegretol should be used carefully and close clinical and frequent laboratory supervision should be maintained throughout treatment in order to detect as early as possible signs and symptoms of a possible blood dyscrasia.

Long-term toxicity studies in rats indicated a potential carcinogenic risk. Therefore, the possible risk of drug use must be weighed against the potential benefits before prescribing carbamazepine to individual patients.

#### Precautions

Monitoring of Haematological and Other Adverse

*Reactions:* Complete blood studies, including platelet counts, and evaluation of hepatic and renal function and urinalysis should be carried out before treatment is instituted. Careful clinical and laboratory supervision should be maintained throughout treatment, including frequent performance of complete blood counts, in order to detect any early signs or symptoms of blood dyscrasia. Should any signs or symptoms or abnormal laboratory findings suggestive of blood dyscrasia or liver disorder occur, Tegretol should be immediately discontinued until the case is carefully reassessed.

#### *Urinary Retention and Increased Intraocular Pressure:*

Because of its anticholinergic action, Tegretol should be given cautiously, if at all, to patients with increased intraocular pressure or urinary retention. Such patients should be followed closely while taking the drug.

*Occurrence of Behavioural Disorders:* Because it is closely related to the other tricyclic drugs, there is some possibility that Tegretol might activate a latent psychosis, or, in elderly patients, produce agitation or confusion, especially when combined with other drugs. Caution should also be exercised in alcoholics.

#### *Use in Patients with Cardiovascular Disorders:*

Tegretol should be used cautiously in patients with a history of coronary artery disease, organic heart disease, or congestive failure. If a defective conductive system is suspected, an E.K.G. should be performed before administering Tegretol, in order to exclude patients with atrioventricular block.

#### *Use in Patients taking Oral Contraceptives:*

In women under treatment with Tegretol, the reliability of oral contraceptives may be adversely affected; such patients should accordingly be advised to use some alternative, non-hormonal method of contraception.

#### *Driving and Operating Hazardous Machinery:*

Because dizziness and drowsiness are possible side effects of Tegretol, patients should be warned about the possible hazards of operating machinery or driving automobiles.

#### Adverse Reactions

The reactions which have been most frequently reported with Tegretol are drowsiness, unsteadiness on the feet, vertigo, dizziness, gastrointestinal disturbances, and nausea. These reactions usually occur only during the initial phase of therapy. They have rarely necessitated discontinuing Tegretol therapy, and can be minimized by initiating treatment at a low dosage.

The more serious adverse reactions observed are the haematologic, hepatic, cardiovascular and dermatologic reactions, which require discontinuation of therapy. The following adverse reactions have been reported:

*Haematological reactions:* Transitory leucopenia, eosinophilia, leucocytosis, thrombocytopenic purpura, agranulocytosis, macrocytic anemia and aplastic anemia. In a few instances, deaths have occurred.

*Hepatic disturbances:* During the long-term administration of Tegretol abnormalities in liver function tests and cholestatic or hepatocellular jaundice have been observed.

*Dermatological reactions:* The following reactions occurred during treatment with Tegretol: skin sensitivity reactions and rashes, erythematous rashes, pruritic eruptions, urticaria, photosensitivity, pigmentary changes, neurodermatitis and in rare cases Stevens-Johnson syndrome, exfoliative dermatitis, alopecia, diaphoresis, erythema multiforme, erythema nodosum, and aggravation of disseminated lupus erythematosus.

*Neurological reactions:* The reactions reported as occurring during treatment with Tegretol include vertigo, somnolence, disturbances of coordination, confusion, headache, fatigue, blurred vision, transient diplopia and oculomotor disturbances, speech disturbances, abnormal involuntary movements and increase in motor seizures. In addition, peripheral neuritis and paresthesia, depression with agitation, talkativeness,

nystagmus, and tinnitus have been reported but only very rarely. There have been some reports of paralysis and other symptoms of cerebral arterial insufficiency but no conclusive relationship to the administration of Tegretol could be established.

*Cardiovascular systems:* Recurrence of thrombophlebitis in patients with a prior history of thrombophlebitis, congestive heart failure, aggravation of hypertension, Stokes-Adams in patients with AV block, hypotension, syncope and collapse, edema, aggravation of coronary artery disease. Some of these complications (including myocardial infarction and arrhythmia) have been associated with other tricyclic compounds.

*Genitourinary reactions:* Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, and impotence. Elevation of BUN, albuminuria and glycosuria also have been observed.

*Digestive tract:* Disturbances associated with Tegretol therapy have included nausea, vomiting, gastric or abdominal discomfort, diarrhoea, anorexia and dryness of the mouth and throat, glossitis and stomatitis.

*Eyes:* There is no conclusive evidence that Tegretol produces pathological changes in the cornea, lens or retina. However, it should be recognized that many phenothiazines and related drugs have been shown to cause eye changes. By analogy, periodic eye examinations, including slitlamp funduscopy and tonometry, are recommended.

Other reactions reported during treatment with Tegretol include fever and chills, lymphadenopathy, aching joints and muscles, leg cramps and conjunctivitis.

#### Dosage and Administration

*Use in Epilepsy (see Indications):* A low initial daily dosage with a gradual increase in dosage is advised. Dosage should be adjusted to the needs of the individual patient.

*Adults and Children over 12 years of age:* Initially, 100 to 200 mg once or twice a day depending on the severity of the case and previous therapeutic history. The initial dosage is progressively increased, until the best response is obtained, up to 600 mg daily. The usual optimal dosage is 600 mg daily, but occasionally dosage up to 800 to 1000 mg have been used for short periods. As soon as disappearance of seizures has been obtained and maintained, dosage should be reduced very gradually until a minimum effective dose is reached.

*Use in trigeminal neuralgia:* The initial daily dosage should be small: 200 mg, taken in two doses of 100 mg each is recommended. The total daily dosage can be increased by 200 mg per day until relief of pain is obtained. This is usually achieved at a dosage between 200 and 800 mg daily, but occasionally up to 1200 mg per day may be necessary. As soon as relief of pain has been obtained and maintained, progressive reduction in dosage should be attempted until a minimum effective dosage is reached. Because trigeminal neuralgia is characterized by periods of remission, attempts should be made to reduce or discontinue the use of Tegretol at intervals of not more than 3 months, depending upon the individual clinical course.

Prophylactic use of the drug in trigeminal neuralgia is not recommended.

Tegretol should be taken in two or three divided doses daily, with meals whenever possible.

#### Dosage Forms

Tegretol is available as a 200 mg white, round, flat bevelled edge single-scored tablet, engraved with Geigy signet.

#### Availability

Bottles of 50 and 500 tablets. Protect from heat and humidity.

Full information available on request.

## Geigy


Mississauga, Ontario  
LSN 2W5

PAAB  
CCPP  
G-2005

See outside back cover

# The Vigilant Sleepwatcher

## ®GRASS Series 8 EEG-Polygraph-Polysomnograph



Polysomnograph means to graph or write many things about sleep. Grass instrumentation has been doing just that beginning with Davis, Loomis et al. (1938), and continuing with Dement and Kleitman (1957). Small wonder that most sleep disorder centers use Grass Recorders as the standard to gather data. Small wonder that neurology departments are extending usage of the Grass Model 8 EEG for sleep studies. A dual purpose Model 8 EEG with Polygraph channels added can be essential for the diagnosis of most clinically defined sleep disorders at night in addition to performing routine daytime clinical EEG.

Special purpose transducers, amplifiers and other modules are being developed to simplify set-up time and operation. Custom input cabling and junctions are

available to satisfy all types of multiple patient sleep laboratory requirements.

The largest model in the series will accommodate a maximum of 25 EEG channels, or other combinations including 16 EEG + 4 DC, 18 EEG + 4 DC, 12 EEG + 6 DC are possible. With suitable sensors and transducers sleep disorder measurements can include:

EEG	EOG
EMG	Upper Airway Airflow
N.P.T.	Oximetry
Limb Movement	Breathing Sounds
Thorax and Abdominal	Respiratory Effort

---and you get the bonus of traditional Grass reliability, designed for 24 hour daily service including a new maxi-size "all-channel fill once a day" inkwell.

GRASS INSTRUMENT COMPANY Tel. 617-773-0002  
101 Old Colony Avenue • P.O. Box 516 • Quincy, MA 02169

© 1983

D149H83

**GRASS**

# SERC®

(betahistine hydrochloride tablets)

## For the management of Vertigo

### ■ Proven efficacy

“(Serc) is now a proven, useful therapeutic agent in the treatment of Ménière’s disease, especially in the control of vertigo.”<sup>1</sup>

### ■ Restores vestibular responses

“In a preliminary trial (Wilmot 1971) using objective testing of both auditory and vestibular function... the results showed statistical significance in favour of Serc.”<sup>2</sup>

### ■ Reduced severity of episodic vertigo

“... a significant improvement in favour of the drug (Serc) with regard to vertigo, tinnitus and deafness. Vertigo was the most responsive symptom.”<sup>1</sup>

### ■ Well tolerated

“No adverse reactions were observed.”<sup>1</sup>

#### REFERENCES:

- 1 Frew, I.J.C. et al: Postgrad. Med. J., 52:501-503, 1976.
- 2 Wilmot, T.J. et al: J. Laryng. Otol: 9:833-840, 1976.

#### PRESCRIBING INFORMATION:

**INDICATIONS:** SERC may be of value in reducing the episodes of vertigo in Meniere's disease. No claim is made for the effectiveness of SERC in the symptomatic treatment of any form of vertigo other than that associated with Meniere's disease.

**DOSAGE AND ADMINISTRATION:** The usual adult dosage has been one to two tablets (4 mg. each) administered orally three times a day.

Recommended starting dose is two tablets three times daily. Therapy is then adjusted as needed to maintain patient response. The dosage has ranged from two tablets per day to eight tablets per day. No more than eight tablets are recommended to be taken in any one day.

SERC (betahistine hydrochloride) is not recommended for use in children. As with all drugs, SERC should be kept out of reach of children.

**CONTRAINDICATIONS:** Several patients with a history of peptic ulcer have experienced an exacerbation of symptoms while using SERC. Although no causal relation has been established SERC is contraindicated in the presence of peptic ulcer and in patients with a history of this condition. SERC is also contraindicated in patients with pheochromocytoma.

**PRECAUTIONS:** Although clinical intolerance to SERC by patients with bronchial asthma has not been demonstrated, caution should be exercised if the drug is used in these patients.

**USE IN PREGNANCY:** The safety of SERC in pregnancy has not been established. Therefore, its use in pregnancy or lactation, or in women of childbearing age requires that its potential benefits be weighed against the possible risks.

**ADVERSE REACTIONS:** Occasional patients have experienced gastric upset, nausea and headache.

**HOW SUPPLIED:** Scored tablets of 4 mg each in bottles of 100 tablets.

**Full prescribing information available on request.**

**UNIMED** Canada Inc.  
Dorval, Quebec H9P 2P4

PAAB  
CCPP







**Lioresal**<sup>®</sup>  
baclofen



## Traitez la spasticité dès le début pour accélérer son rétablissement.

Une prompt intervention avec le Lioresal, avant qu'une incapacité majeure ne s'installe, peut grandement contribuer à la réadaptation.<sup>1</sup>

- Lioresal aide à soulager la spasticité due aux lésions de la moelle épinière, à la sclérose en plaques et autres affections médullaires.
- Lioresal agit principalement au niveau de la moelle épinière éliminant le risque de sédation excessive gênante.<sup>2</sup>
- Lioresal améliore la perspective d'un traitement prolongé.<sup>1</sup>

## avant qu'il ne soit trop tard.

# Lioresal<sup>®</sup>...

PAAB  
CCPP  
G-3017

See page xiv

**Geigy**

Mississauga, Ontario  
L5N 2W5


**Some drugs  
are just too important  
to allow substitution**

# Tegretol<sup>®</sup>

Carbamazepine

**The original carbamazepine  
for the treatment of epilepsy.  
Because there is no substitute  
for experience.**

**Yours or Ours.**



**Geigy**

Mississauga, Ontario  
L5N 2W5

PAAB  
CCPP